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Doxorubicin (DOX) is an anticancer agent with a wide spectrum
of activity. Cumulative dose-related cardiotoxicity, however, is a
major side-effect of DOX, in addition to the acute toxicities, such
as myelosuppression, nausea and vomiting. The success of DOX,
and its limitations in clinical use, have directed research endeav-
ours for the development of analogues of DOX with an improved
therapeutic index. Among these are iododoxorubicin, AD-32 and
epidoxorubicin (Weiss, 1992). Iododoxorubicin was noted to be
promising in phase I trials, but in phase II trials the response rate
was too low to warrant further development. AD-32 has greater
anti-tumour activity, and less cardiotoxicity, than DOX, but drug
formulation and solubility problems prevented its further clinical
development. Of the available analogues, only epidoxorubicin
appears to have a reduced cardiotoxicity with retention of anti-
tumour activity and is in use in current cancer chemotherapy. 
Another way to improve the selectivity and efficacy of
chemotherapy is the use of non-toxic prodrugs that are preferen-
tially converted into active anticancer agents at the tumour site
(Sinhababu and Thakker, 1996). N-L-leucyl-DOX is a prodrug 
of DOX, to be activated by tumour peptidases (Deprez-de
Campeneere et al, 1982). In human ovarian cancer xenografts, N-
L-leucyl-DOX was more effective than DOX (Boven et al, 1992).
Clinical studies on N-L-leucyl-DOX, however, have indicated
premature activation of the prodrug in the circulation, because of
which the selectivity of the prodrug would be reduced (de Jong 
et al, 1992). Elevated enzyme levels in tumour tissue have been
reported for b-glucuronidase (Connors and Whisson, 1966).
Bosslet et al (1995) and Schumacher et al (1996) have shown that
this enzyme is released in the extracellular space as a result of
necrosis in tumours. The enzyme can only be detected in very 
low concentrations in the circulation (Fishman, 1970). Therefore,
b-glucuronidase may be exploited for the specific activation of
glucuronide prodrugs in tumour tissue. 
We have developed glucuronide derivatives of anthracyclines
and showed that these prodrugs, such as epirubicin-glucuronide
(Haisma et al, 1992) and daunorubicin-glucuronides (Leenders 
et al, 1995; Houba et al, 1996), are relatively non-toxic in vitro and
can be activated by b-glucuronidase to yield the active anthracy-
cline. Treatment with the glucuronide prodrug daunorubicin-GA3
(DNR-GA3) induced a better tumour growth delay than daunoru-
bicin (DNR) when studied at equitoxic doses in 3 human ovarian
cancer xenografts which were sensitive to DNR (Houba et al,
1998). Comparison of the distribution and pharmacokinetics of
DNR and DNR-GA3 demonstrated that the prodrug DNR-GA3
was selectively activated by human b-glucuronidase present in the
tumours and resulted in a higher DNR AUC in tumours and lower
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DNR AUCs in normal tissues (Houba et al, 1999). Our treatment
results with a DNR prodrug are encouraging, but solid tumour
types show better sensitivity to DOX than to DNR. In analogy, this
has led to the synthesis of the prodrug of DOX: N-[4-doxorubicin-
N-carbonyl (oxymethyl) phenyl] O-b-glucuronyl carbamate
(DOX-GA3; Figure 1). DOX-GA3 is a derivative of DOX in
which the glucuronic acid moiety is linked to the anthracycline via
a synthetic spacer, designed to increase the hydrolysis by human 
b-glucuronidase. We anticipate that this prodrug may have a
broader application in the treatment of cancer. 
In the present experiments we compared the antiproliferative
effects of DOX-GA3 and DOX in vitro, and calculated the Km and
Vmax of DOX-GA3 hydrolysed by human b-glucuronidase. We
studied whether DOX-GA3 was specifically activated to DOX by b-
glucuronidase in tumour tissue. To this end, the distribution of DOX
released from DOX-GA3 was compared with that of DOX alone in
mice bearing OVCAR-3 xenografts in tumour tissue as well as in
normal organs at several time-points after injection. After deter-
mination of the maximum tolerated dose (MTD) of DOX-GA3 in
OVCAR-3-bearing nude mice, we compared the anti-tumour effi-
cacy of DOX-GA3 with that of DOX. As large tumours have more
necrosis than small tumours and are therefore expected to contain
higher levels of extracellular b-glucuronidase, special attention was
paid to the influence of the tumour size on drug effects. 
MATERIALS AND METHODS 
Materials 
The human ovarian cancer cell line NIH:OVCAR-3 (Hamilton 
et al, 1983) was grown in Dulbecco’s modified Eagle’s medium
(Life Technologies, Paisley, Scotland) supplemented with 
10% heat- inactivated fetal calf serum (ICN, Costa Mesa, CA), 
50 IU ml–1 penicillin (ICN) and 50 mg ml–1 streptomycin (ICN) in a
humidified atmosphere containing 5% CO2 at 37˚C. 
Doxorubicin (DOX, Pharmachemie BV, Haarlem, The
Netherlands) was purchased as a powder. The prodrug N-[4-
doxorubicin-N-carbonyl (oxymethyl) phenyl] O-b-glucuronyl
carbamate (DOX-GA3) was synthesized as described (Leenders 
et al, 1999). Stock solutions of DOX and DOX-GA3 were
prepared in sterile water and stored at –20˚C. 
Characterization of DOX-GA3 in vitro 
The purity and stability of DOX-GA3 and the activation of DOX-
GA3 in the presence of b-glucuronidase was determined in 0.1%
(w/v) BSA/PBS at pH 6.8 and 37˚C. Samples were taken after 
24 h and were analysed with reversed-phase HPLC as described
(Houba et al, 1999). 
In each cluster of runs standards of DOX-GA3 and DOX were
included, at the beginning and at the end of the cluster. The peak
areas from the elution peaks in the chromatograms were deter-
mined by integration using the program Gyncosoft (Gynkotek,
Version 5.3E). Calibration of the system was performed as
described (de Jong et al, 1991) and the detection limit was
0.01 mM (pro)drug. 
The half-life time of hydrolysis of the prodrug by human
recombinant  b-glucuronidase (Houba et al, 1996) was determined
in PBS at 37˚C and pH 6.8, reflecting the tumour interstitial 
pH (Martin and Jain, 1994), at concentrations of the enzyme 
(1 mg ml–1) and the prodrug (100 mM) assumed to be clinically
relevant (Houba et al, 1999). The prodrug and the enzyme were
diluted in 0.1% (w/v) BSA/PBS at pH 6.8. After incubation at
37˚C the reaction was stopped by adding methanol. Samples were
analysed by HPLC as described above. 
To further characterize the enzymatic conversion of the
prodrugs by human b-glucuronidase Km and Vmax values were
determined. A range of prodrug concentrations (5 ´ 10–5 to
6 ´ 10–3 M) was tested against a human b-glucuronidase concen-
tration of 1 mg ml–1 to determine the hydrolysis expressed as Km
and Vmax values. After incubation for 30 min at 37˚C the reaction
was stopped by adding methanol. Samples were analysed by
HPLC and Km and Vmax values were calculated from direct linear
plots as described by Eisenthal and Cornish-Bowden (Eisenthal
and Cornish-Bowden, 1974). 
Antiproliferative effects 
The in vitro antiproliferative effects of drug and prodrug were
determined in OVCAR-3 cells as previously described (Houba 
et al, 1996). The antiproliferative effect was expressed as the IG50
value, which is the (pro)drug concentration that gives 50% growth
inhibition when compared with control cell growth. 
Human ovarian cancer xenograft OVCAR-3 
All animal experiments were approved by the Institution Animal
Experiments Committee and performed in accord with the institu-
tion guidelines. Female athymic nude mice (Hsd: athymic nude-
nu; Harlan Cpb, Horst, The Netherlands) were handled under
specified pathogen-free conditions. The human ovarian cancer
xenograft OVCAR-3 has been described earlier (Molthoff et al,
1991). The histology shows a poorly differentiated serous adeno-
carcinoma and tumours have a mean volume-doubling time of
5.0 days. Tumours from previous recipients were transferred by
implanting tissue fragments with a diameter of 2–3 mm into both
flanks of 8–10-week-old mice. Upon growth, tumours were
measured twice a week by the same observer. The tumour volume
was calculated by the equation length ´ width ´ thickness ´ 0.5,
and expressed in mm3. 
Maximum tolerated dose of DOX and DOX-GA3 
The MTD was defined as the dose that gives a mean reversible loss
of approximately 10% of the initial weight within 2 weeks after
the first injection. Animals dying within 2 weeks after the final
injection were considered as toxic deaths. The MTD of DOX in
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OVCAR-3-bearing mice was established earlier being 8 mg kg–1
i.v. weekly ´ 2 (Boven et al, 1990). The MTD of DOX-GA3 in
OVCAR-3-bearing mice was found to be 500 mg kg–1 i.v. weekly
´ 2. No toxic deaths occurred and the maximum weight loss was
approximately 10%. 
Distribution of DOX and DOX-GA3 in tumour and
normal tissues 
Nude mice bearing s.c. xenografts with a mean volume of
600 mm3 were injected i.v. with DOX (8 mg kg–1) or DOX-GA3
(250 mg kg–1) to determine their distribution and pharmacoki-
netics. Because of the limited availability of DOX-GA3 we inves-
tigated DOX-GA3 at half of the MTD. At different time-points
ranging from 1 min to 24 h blood, tumours, liver, heart and
kidneys were removed in groups of three OVCAR-3-bearing mice
per time-point. Blood was collected in heparinized vials and
centrifuged at 16 000 g for 5 min. To plasma 1/100 volume of
100 mM D-glucaric acid-1,4-lactone monohydrate (saccharolac-
tone; Fluka, Buchs, Germany) was added to prevent hydrolysis of
DOX-GA3 by b-glucuronidase. Saccharolactone is a selective
competitive inhibitor of activity of b-glucuronidase. The activity
of the enzyme was almost completely abolished (>99%) at the
used concentration of 1 mM (data not shown). 
After blood sampling the tumour, liver, heart and kidney tissues
were collected and immediately frozen in liquid nitrogen and
stored at –20˚C until preparation for HPLC analysis (Houba et al,
1999). In control tissue homogenates and serum samples, incub-
ated with DOX-GA3 at concentrations up to 1 mM and stored for
up to 4 weeks at –20˚C, less than 0.1% activation to doxorubicin
was observed (data not shown). 
Data were analysed with the software program Topfit, in order
to calculate half-life times and area under the concentration versus
time curves (AUC). Differences between drug concentrations per
time-point were evaluated with Student’s t-test. 
Drug targeting index (DTI) 
The efficiency of targeting can be described as a drug targeting
index (Kearney, 1996). Assuming that the AUCs at the response
(tumour) and toxic sites (bone marrow, heart) reflect the relative
activity and toxicity of the drug, the DTI can be defined as follows: 
DTI =
AUC (R, target) / AUC (T, target)
AUC (R, non-target) / AUC (T, non-target)
where R represents the response site (tumour) and T the toxic site
after targeted delivery (DOX-GA3, target) and non-targeted
delivery (DOX, non-target), respectively. A value higher than 1
indicates targeting to the response site. 
Anti-tumour activity of anthracyclines in vivo 
Mice bearing OVCAR-3 tumours were used to compare DOX 
with DOX-GA3 anti-tumour effects. At the start of the treatment
(day 0), mice were grouped in order to obtain similarities in the
mean tumour volume. For small tumours the mean volume was 125
mm3 and for larger tumours 400 mm3. Control and treatment groups
consisted of 6 animals each. DOX was given in a dose of 
8 mg kg–1 i.v. weekly ´ 2 (MTD) to mice with small and larger
tumours. DOX-GA3 was studied at 500 mg kg–1 i.v. weekly ´ 2
(MTD) in groups with small and larger tumours. Mice were weighed
twice a week and tumours were measured on the same days. 
For evaluation of drug effects the relative tumour volume was
expressed by the formula VT/V0, where VT is the volume on any
given day and V0is the volume on day 0. The ratio between the mean
of the relative volumes of treated tumours and that of control tumours
´ 100% (T/C%) was assessed on each day of measure-ment and used
to calculate the percentage of maximum GI (GI = 100%– T/C%). The
relative tumour volume was calculated and normalized for growth of
the control tumours. As a measure of the duration of the treatment
effects, the days for each tumour to double twice in volume (TD1®4)
was calculated. If a tumour did not reach 2 volume doubling times
this volume was extrapolated from the last 2 available measurements.
Differences in mean TD1®4 between groups were evaluated with
Student’s  t-test. In addition, differences in efficacy between the treat-
ment groups of small vs large tumours were expressed as the specific
growth delay (SGD) (Boven et al, 1988). The SGD was calculated
according to the following formula: 
SGD =
TD1®4 treated – TD1®4 control
TD1®4 control
RESULTS 
Characterization of DOX-GA3 in vitro 
Our initial experiments sought to determine enzymatic activation
of the glucuronide prodrug DOX-GA3 to the parent drug DOX. To
this end DOX-GA3 was incubated with human b-glucuronidase.
HPLC analysis showed that DOX-GA3 was more than 99.9% pure
and could be completely hydrolysed to DOX in the presence of
excess human b-glucuronidase to DOX, and no spacer-drug inter-
mediate was detectable. A sample chromatogram from an inter-
mediate timepoint (30 min) is shown in Figure 2. The prodrug,
incubated at the clinically relevant concentrations of 100 mM for
DOX-GA3 and of 1 mg ml–1 for the enzyme, was hydrolysed at
pH 6.8 and 37˚C with a t1/2 of 140 min. 
Based on the in vitro cleavage experiments at different
prodrug concentrations at pH 6.8 and at 37˚C, Vmax and Km were
calculated from direct linear plots as described by Eisenthal
(Eisenthal and Cornish-Bowden, 1974). For DOX-GA3 a Vmax of
25.0 mmol min–1 mg–1 and a Km of 1100 mM was found. 
We next analysed the in vitro antiproliferative effects of DOX
and DOX-GA3. For DOX the IC50 was 0.12 mM (SD ± 0.06) and
the prodrug was more than 100-times less capable of inhibiting
cell growth with an IC50 value of 22 mM (SD ± 7.6). This was prob-
ably caused by activation of the prodrug through b-glucuronidase
released from dead cells because we were unable to detect DOX in
the prodrug preparation. When DOX-GA3 was incubated with an
excess of b-glucuronidase, the antiproliferative effect returned to a
value similar to that of DOX (0.16 mM; SD ± 0.06). This indicated
that the prodrug was completely activated to the parent drug under
these conditions (Figure 3). 
Distribution and kinetics in plasma, tumour and normal
tissues 
The distribution of DOX (8 mg kg–1) and DOX-GA3 (250 mg
kg–1) in plasma, tumour and normal tissues was compared inTumour-selective chemotherapy 553
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OVCAR-3-bearing mice (Figure 4). First, the in vivo stability 
of the prodrug was tested in non-tumour bearing mice.
Administration of DOX-GA3 (250 mg kg–1) in these animals
resulted in a drug/prodrug ratio of 0.001 (t = 30 min) in plasma
and no other major peaks were visible. These findings indicate the
lack of activation by endogenous b-glucuronidase in non-
tumour-bearing animals. Next, we investigated this effect 
in tumour-bearing animals. After administration of DOX-GA3,
the prodrug peak concentration was 1370 nmol ml–1 (t =1 min) in
plasma and a drug peak concentration of 2.17 nmol ml–1 was
found. After administration of DOX, a considerably higher peak
concentration of 16.4 nmol ml–1 was detected in plasma. The ratio
of drug/prodrug (0.002) was similar to that found in non-tumour-
bearing animals, indicating that the systemic activation of prodrug
is not increased by the presence of tumour. 
DOX administration resulted in DOX peak concentrations in
mouse organs that where highest in kidney (90.2 nmol g–1)
followed by liver (46.0 nmol g–1), and heart (15.9 nmol g–1).
Prodrug injection also resulted in highest peak DOX concentra-
tions in kidney (70.8 nmol g–1) followed by liver (14.2 nmol g–1)
and heart (3.27 nmol g–1) at 30 min to 2 h after injection of the
prodrug. These values were 2 to 5 times lower than those found
after DOX administration, except for kidney tissue where it was
slightly lower (Figure 4). 
Administration of DOX resulted in a peak concentration of the
drug in OVCAR-3 tumour tissue of 2.14 nmol g–1 at 1 min after
injection (Figure 4). The prodrug DOX-GA3 had a peak of DOX-
GA3 of 44.0 nmol g–1 (t = 30 min). A significantly higher DOX
level of 9.57 nmol g–1 (t = 2 h) was found after prodrug injection
(P < 0.001; t = 2 h) than after administration of the parent drug. In
tumours, DOX was well retained both after DOX and DOX-GA3
administration, and the elimination of DOX from the tumour was
not different after drug or after prodrug administration (Figure 4). 
As an example for the selective activation of the prodrug at the
tumour site, the ratios of the DOX concentrations at 2 h after
DOX-GA3 and DOX administration are given for plasma, normal
tissues and tumour tissue in Figure 5. At this time, the highest
DOX level in tumour tissue was measured after prodrug adminis-
tration. It is clear that the DOX concentrations in normal tissues
were lower after prodrug than after DOX administration, except
for the kidney. 
Areas under the concentration versus time curve 
As a measure of drug exposure, the AUC of DOX was calculated
for plasma, normal mouse organs and tumour tissue by the trape-
zoidal rule using the available time-points and the software
program Topfit (Table 1). The plasma AUC of DOX after adminis-
tration of DOX (0.342 mmol min ml–1) was 8-fold higher than the
AUC of DOX after injection of DOX-GA3 (0.042 mmol min–1
ml–1), with DOX given at the MTD and prodrug at half of the
MTD. For the liver and the heart the respective AUCs for DOX
were 1.8- and 3.1-fold higher and for the kidney the AUC was 2.0
times lower after DOX than after prodrug administration. Of
importance, in OVCAR-3 tumour tissue the AUC of DOX from
DOX-GA3 was 10-fold higher than that after DOX. 
Drug targeting index (DTI) 
The efficiency of targeting can be described as a drug targeting
index (Kearney, 1996). We calculated the DTI for plasma (as a
surrogate for bone marrow) and heart tissue because these are the
major organs for anthracycline toxicity. For plasma a high DTI of
81.4 was calculated and for heart tissue the DTI was 31.4. This
analysis thus confirms the selective activation of the prodrug
DOX-GA3 in tumours. 
Anti-tumour activity of DOX and DOX-GA3 in vivo 
The administration of DOX (8 mg kg–1 ´ 2) resulted in a maximum
G1 of 56% in small OVCAR-3 xenografts. At an equitoxic dose
the molar amount of DOX-GA3 (500 mg kg–1 ´ 2) that could be
administered was 38-fold higher when compared with that of the
parent drug. In OVCAR-3 xenografts DOX-GA3 induced a
maximum G1 of 87%, which was considerably higher than that of
DOX (Table 2, Figure 6). The augmented anti-tumour effect of
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DOX-GA3 was also demonstrated by an increase of the duration
of the anti-tumour effect, expressed as TD1®4, from 11.5 to 32.4
days, which was significant (P < 0.01, Table 2).
To study the effect of tumour size on the tumour growth inhibi-
tion DOX-GA3 was administered to animals bearing small or
larger tumours, where larger tumours are expected to have more
necrosis and, thus, more b-glucuronidase in the extracellular
space. Larger tumours grew much slower than small tumours
(TD1®4, small 8.0 days, large 15.4 days). In animals treated with
DOX, the maximum growth inhibition was similar for both small
and larger tumours, 56 and 52% respectively. DOX-GA3 treatment
of larger tumours indeed resulted in a better inhibition of growth.
The SGD in OVCAR-3 tumours increased from 2.7 to 3.9 for
small and larger tumours, respectively. 
DISCUSSION 
In this study we describe a new doxorubicin prodrug, DOX-GA3,
designed for specific activation to DOX at the tumour site. In nude
mice bearing human ovarian cancer xenografts we showed
that equitoxic doses of (pro)drug resulted in better anti-tumour
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effects after DOX-GA3 than after DOX. The administration of 
DOX-GA3 led to specific activation of the prodrug at the tumour
site yielding higher concentrations of DOX in tumour tissue than
after DOX injection. The 10-fold higher AUC of DOX from DOX-
GA3 thus explains the better anti-tumour effect measured for
DOX-GA3 when compared with DOX. Furthermore, the efficacy
of DOX-GA3 appeared to be more pronounced in larger tumours
when compared with the efficacy in small tumours. In the animals
treated with DOX, the larger tumours were not more sensitive than
the smaller tumours. 
Our findings are consistent with other studies employing this
approach. In this regard, as early as 1966 Connors and Whisson
(Connors and Whisson, 1966) have shown that glucuronide
prodrugs can be activated in tumours by b-glucuronidase. 
b-Glucuronidase is present extracellularly in necrotic tumour areas
found in tumours larger than 3 mm diameter (Bosslet et al, 1995;
Schumacher et al, 1996), whereas in normal tissues it is present
only intracellularly inside lysosomes and microsomes (Levvy and
Conchie, 1966). A clinical trial of aniline mustard was performed
in patients with advanced cancer (Young et al, 1976). The drug
used, aniline mustard, is transformed into the prodrug p-hydroxy
aniline glucuronide which acts as a substrate for b-glucuronidase
found in tumours. A correlation was shown between b-glucuro-
nidase activity and patient response. However, the necessary high
levels of b-glucuronidase were observed only rarely. The limited
success of this trial is possibly due to the slow activation of the
aniline glucuronide by the enzyme. The glucuronide prodrugs
DNR-GA3 and DOX-GA3 were designed to be rapidly activated
by human b-glucuronidase at a pH of 6.8 (Houba et al, 1996). 
For DOX-GA3 a Vmax of 25.0 mmol min–1 mg–1 and a Km of 
1100 mM was found. The relatively high Km is slightly lower 
than the Km observed with the synthetic substrate substrate 4-
nitrophenyl-glucuronide (Tomino and Paigen, 1975) (1.3 mM) and
another glucuronide prodrug (1.3 mM) described by Bosslet et al
(1994). The relatively high Km may be beneficial for improving
tumour:non-tumour ratios of active drug: prodrug activation will
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Figure 6 Tumour growth in mice bearing small or larger OVCAR-3
xenografts after i.v. treatment with maximum tolerated doses of DOX 
(day 0, 7) or DOX-GA3 (day 0,7). s, control (small tumours); l, DOX
8 mg kg–1 (small tumours); n, DOX-GA3 500 mg kg–1 (small tumours); 
s s, control (larger tumours); l l, DOX 8 mg kg–1 (larger tumours);
n n, DOX-GA3 500 mg kg–1 (larger tumours). Bars, ± SEM 
Table 1 AUCa of DOX in plasma and tissues of OVCAR-3-bearing mice after i.v. administration of DOX 
(8 mg kg–1) or DOX-GA3 (250 mg kg–1) 
Treatment Plasma Liver Heart Kidney Tumour 
(mmol min–1 ml–1)( mmol min–1 g–1)( mmol min–1 g–1)( mmol min–1 g–1)( mmol min–1 g–1) 
DOX 0.342 24.5 9.70 33.2 1.31 
DOX-GA3 0.042 13.4 3.09 65.0 13.1 
aThe AUC (0–24 h) using the available time-points. 
Table 2 Anti-tumour effect with DOX or DOX-GA3 in mice bearing OVCAR-3 xenografts 
Treatment Size Dose i.v.  Days Tumour volumea Weight loss  Weight day 14  GI %c TD1®4
b
(mg kg–1) mean ± SEM  % ± SD % ± SD days ± SEM (n)
Control Small  128 ± 29 n.a. 111.0 ± 4.7 n.a. 8.0 ± 0.6 (10) 
DOX Small 8 0,7 123 ± 19 1.3 ± 2.0 104.4 ± 3.4 56 11.5 ± 1.8 (10) 
DOX-GA3 Small 500 0,7 123 ± 19 5.1 ± 3.4 99.0 ± 3.1 87 32.4 ± 5.4 (11)d,e
Control Large  0,7 390 ± 97 n.a. 106.8 ± 5.5 n.a. 15.4 ± 1.4 (10) 
DOX Large 8 0,7 534 ± 128 2.8 ± 0.2 101.5 ± 2.8 52 21.5 ± 0.7 (5) 
DOX-GA3 Large 500 0,7 458 ± 107  9.6 ± 7.2 91.9 ± 6.5 88 75.1 ± 11.8 (10)d
n.a., not applicable; aat start of treatment; btumour volume doubling time in days from a relative volume of 1 to 4; cmaximum growth inhibition; dP < 0.001 when
compared with control; eP < 0.01 when compared with DOX.556 PHJ Houba et al 
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be relatively slow at sites with low levels of enzyme. In this
regard, a Km of 1 mM was shown to be optimal by pharmaco-
kinetic modelling by Yuan et al (1991). The half-life of hydrolysis
at clinically relevant concentrations of the prodrug and human 
b-glucuronidase was 140 min. Although this seems to be far from
optimal, the time to reach toxic concentrations of DOX in tumour
tissue is much shorter, only a few minutes (Figure 4). 
DOX is a lipophilic molecule and, as a consequence, it rapidly
penetrates into tissues. Therefore, normal tissue DOX levels are
relatively high after DOX administration and may account for
unfavourable side-effects (Figure 4). The hydrophilic glucuronide
moiety of DOX-GA3 prevents rapid diffusion of prodrug into
cells. This is confirmed by the high peak plasma concentrations 
of DOX-GA3 and its rapid clearance from plasma, tumour and
normal tissues. 
In plasma, heart and liver tissues the concentrations of DOX
were lower after DOX-GA3 administration than after injection 
of DOX itself. Lower concentrations of DOX in the heart are of
advantage, because this organ is the site of cumulative dose-
limiting toxicity of DOX. In the kidney, higher concentrations of
DOX from DOX-GA3 than after DOX were measured. These
higher concentrations may be explained by the presence of 
b-glucuronidase in the renal tubular cells. This should not result
in increased toxicity as in patients renal insufficiency is rarely
observed after DOX administration. 
In OVCAR-3 xenografts higher concentrations of DOX from
DOX-GA3 were detectable than after administration of DOX.
Presumably, DOX-GA3 was activated by b-glucuronidase present
in tumour tissue in the extracellular space, but not in normal
tissues. Therefore, higher AUC values of DOX from DOX-GA3
were reached than after DOX administration. These higher AUC
values explain the better inhibition of tumour growth in 
OVCAR-3 xenografts observed after DOX-GA3 administration
when compared with DOX, when given at an equitoxic dose. The
TD1®4  increased significantly (P < 0.001) from 11.5 days
(8 mg kg–1 DOX weekly ´ 2) to 32.4 days (500 mg kg–1 DOX-GA3
weekly ´ 2). 
It was hypothesized that larger tumours contain more necrosis
and, thus, more b-glucuronidase would be available to activate
DOX-GA3, as has also been described by the group of Bosslet
(Bosslet et al, 1995). Indeed, we calculated a higher SGD for
larger tumours (SGD = 3.9) than for small tumours (SGD = 2.7).
We reported a similar finding for the prodrug DNR-GA3 where the
SGD increased in OVCAR-3 and MRI-H-207 xenografts when
treatment of larger tumours was compared with that of small
tumours (Houba et al, 1998). With respect to the clinical applica-
tion, our findings are of interest in the context of the treatment of
patients with large tumour deposits. 
The glucuronide-prodrugs will probably not be activated in
small tumours because they are non-necrotic and thus do not
contain extracellular b-glucuronidase. In these tumours the
prodrug may be used in combination with a second approach:
Antibody-Directed Enzyme-Prodrug Therapy (ADEPT). In
ADEPT, prodrugs are activated in tumours by an administered
tumour-specific monoclonal antibody-enzyme conjugate. We have
shown earlier that a conjugate of monoclonal antibody 323/A3 and
human b-glucuronidase bound to tumour cells can activate anthra-
cycline prodrugs in an efficient manner (Haisma et al, 1992). In
addition to the chemically prepared conjugate a single chain Fv
fusion protein may be used (Haisma et al, 1998). If such a tumour-
specific conjugate is administered before DOX-GA3 injection,
activation could also occur in the non-necrotic smaller tumour
lesions such as micrometastases or minimal residual disease. 
In conclusion, DOX-GA3 is a non-toxic prodrug which is
specifically activated to DOX in tumour tissue by b-glucuronidase
released by necrotic cells. Although the treatment schedule is not
yet optimized we have already demonstrated that DOX-GA3 has a
higher therapeutic index than DOX. These results are encouraging
and warrant clinical development of DOX-GA3. 
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